Lung cancer biology: A genetic and genomic perspective

Clinical and Translational Oncology

Volumn 11, Issue 5, 2009, Pages 263-269

  Sánchez Céspedes, Montse ^a  

^a HOSPITAL DURAN I REYNALS   (Spain)

Author keywords

Cancer genes; Lung cancer; Oncogenes; Somatic mutations; Tumour suppressors

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; BRG1 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE LKB1; RAS PROTEIN;

CANCER GENETICS; CANCER SUSCEPTIBILITY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOMICS; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; REVIEW; SIGNAL TRANSDUCTION; GENETICS; LUNG TUMOR; SMOKING;

GENOMICS; HUMANS; LUNG NEOPLASMS; SMOKING;

EID: 68849128295     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-009-0353-7     Document Type: Review

References (64)

1. M. Sanchez-Cespedes 2003 Dissecting the genetic alterations involved in lung carcinogenesis Lung Cancer 40 111 121 12711111 10.1016/S0169-5002(03)00033- 3 (Pubitemid 36438711)
2. L. Ding G. Getz D.A. Wheeler, et al. 2008 Somatic mutations affect key pathways in lung adenocarcinoma Nature 455 1069 1075 18948947 10.1038/nature07423 1:CAS:528:DC%2BD1cXht1yju73J
3. Blanco R, Iwakawa R, Tang M et al (2009) A gene-alteration profile of human lung cancer cell lines. Hum Mut (in press)
4. G.A. Otterson R.A. Kratzke A. Coxon, et al. 1994 Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB Oncogene 9 3375 3378 7936665 1:CAS:528:DyaK2cXmslOktbY%3D
5. J. Yokota T. Akiyama Y.K. Fung, et al. 1988 Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung Oncogene 3 471 475 2856251 1:CAS:528:DyaL1MXlsFWlsg%3D%3D
6. J. Carretero P.P. Medina R. Pio, et al. 2004 Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene Oncogene 23 4037 4040 15021901 10.1038/sj.onc.1207502 1:CAS:528:DC%2BD2cXjvVKgurg%3D (Pubitemid 38747933)
7. W.H. Westra R.J. Slebos G.J. Offerhaus, et al. 1993 K-ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung Cancer 72 432 438 8319174 10.1002/1097-0142(19930715) 72:2<432::AID-CNCR2820720219>3.0.CO;2-# 1:STN:280:DyaK3szgs1GrtQ%3D%3D
8. R.J.C. Slebos R.H. Hruban O. Dalesio, et al. 1991 Relationship between K-ras oncogene activation and smoking in adenocarcinomas of the human lung J Natl Cancer Inst 83 1024 1027 2072410 10.1093/jnci/83.14.1024 1:STN:280:DyaK3MzgtlGquw%3D%3D
9. T.J. Lynch D.W. Bell R. Sordella, et al. 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 20 2129 2139 10.1056/NEJMoa040938 (Pubitemid 38637993)
10. J.G. Paez P.A. Janne J.C. Lee, et al. 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497 1500 15118125 10.1126/science.1099314 1:CAS:528:DC%2BD2cXksVGmsbs%3D (Pubitemid 38720929)
11. G.V. Scagliotti G. Selvaggi S. Novello, et al. 2004 The biology of epidermal growth factor receptor in lung cancer Clin Cancer Res 10 4227s 4232s 15217963 10.1158/1078-0432.CCR-040007 1:CAS:528:DC%2BD2cXltFWlsro%3D (Pubitemid 38812451)
12. E. Conde B. Angulo M. Tang, et al. 2006 Molecular context of the epidermal growth factor receptor mutations: evidence for the activation of mTOR/S6K signaling Clin Cancer Res 12 710 717 16467080 10.1158/1078-0432.CCR-05- 1362 1:CAS:528:DC%2BD28XhtFeitbw%3D (Pubitemid 43259849)
13. H. Davies G.H. Bignell C. Cox, et al. 2002 Mutations of the BRAF gene in human cancer Nature 417 949 954 12068308 10.1038/nature00766 1:CAS:528:DC%2BD38XkvVagsLo%3D (Pubitemid 34716871)
14. P. Stephens C. Hunter G. Bignell, et al. 2004 Lung cancer: intragenic ERBB2 kinase mutations in tumours Nature 431 525 526 15457249 10.1038/431525b 1:CAS:528:DC%2BD2cXnvFCntLg%3D
15. M. Sanchez-Cespedes P. Parrella M. Esteller, et al. 2002 Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung Cancer Res 62 3659 3662 12097271 1:CAS:528:DC%2BD38XltF2jtLo%3D
16. S. Matsumoto R. Iwakawa K. Takahashi, et al. 2007 Prevalence and specificity of LKB1 genetic alterations in lung cancers Oncogene 26 5911 5918 17384680 10.1038/sj.onc.1210418 1:CAS:528:DC%2BD2sXps12nur0%3D
17. A.K. Wong F. Shanahan Y. Chen, et al. 2000 BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines Cancer Res 60 6171 6177 11085541 1:CAS:528:DC%2BD3cXotV2lsbk%3D
18. P.P. Medina O.A. Romero T. Kohno, et al. 2008 Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines Hum Mutat 29 617 662 18386774 10.1002/humu.20730 1:CAS:528:DC%2BD1cXmsVOnsr8%3D (Pubitemid 351614585)
19. M. Sanchez-Cespedes 2007 A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome Oncogene 26 7825 7832 17599048 10.1038/sj.onc.1210594 1:CAS:528:DC%2BD2sXhsVaisr7E (Pubitemid 350261789)
20. P.P. Medina M. Sanchez-Cespedes 2008 Involvement of the chromatin-remodeling factor BRG1/SMARCA4 in human cancer Epigenetics 3 64 68 18437052
21. M.J. Kelley K. Nakagawa S.M. Steinberg, et al. 1995 Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines J Natl Cancer Inst 87 756 761 7563154 10.1093/jnci/87.10.756 1:CAS:528:DyaK2MXms12gur4%3D
22. E. Forgacs E.J. Biesterveld Y. Sekido, et al. 1998 Mutation analysis of the PTEN/MMAC1 gene in lung cancer Oncogene 17 1557 1565 9794233 10.1038/sj.onc.1202070 1:CAS:528:DyaK1cXms1OgtrY%3D
23. S.P. Hussain P. Amstad K. Raja, et al. 2001 Mutability of p53 hotspot codons to benzo(a)pyrene diol epoxide (BPDE) and the frequency of p53 mutations in nontumorous human lung Cancer Res 61 6350 6355 11522624 1:CAS:528: DC%2BD3MXmsF2js7g%3D
24. J.D. Carpten A.L. Faber C. Horn, et al. 2007 A transforming mutation in the pleckstrin homology domain of AKT1 in cancer Nature 448 439 444 17611497 10.1038/nature05933 1:CAS:528:DC%2BD2sXotFajtbk%3D (Pubitemid 47123510)
25. M. Soda Y.L. Choi M. Enomoto, et al. 2007 Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 561 566 17625570 10.1038/nature05945 1:CAS:528:DC%2BD2sXosVSrtrs%3D (Pubitemid 47206930)
26. R.K. Thomas A.C. Baker R.M. Debiasi, et al. 2007 High-throughput oncogene mutation profiling in human cancer Nat Genet 39 347 351 17293865 10.1038/ng1975 1:CAS:528:DC%2BD2sXitVOktrs%3D (Pubitemid 46328493)
27. B. Vogelstein K.W. Kinzler 2004 Cancer genes and the pathways they control Nat Med 10 789 799 15286780 10.1038/nm1087 1:CAS:528: DC%2BD2cXmtFWrt7o%3D (Pubitemid 39070849)
28. R.J. Hung J.D. McKay V. Gaborieau, et al. 2008 A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25 Nature 452 633 637 18385738 10.1038/nature06885 1:CAS:528:DC%2BD1cXktFCgtrs%3D
29. C.I. Amos X. Wu P. Broderick, et al. 2008 Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25 Nat Genet 40 616 622 18385676 10.1038/ng.109 1:CAS:528:DC%2BD1cXltFylurw%3D (Pubitemid 351601203)
30. M.R. Spitz C.I. Amos Q. Dong, et al. 2008 The CHRNA5-A3 region on chromosome 15q24-25.1 is a risk factor both for nicotine dependence and for lung cancer J Natl Cancer Inst 100 1552 1556 18957677 10.1093/jnci/djn363 1:CAS:528:DC%2BD1cXhtlGhurnL
31. J.D. McKay R.J. Hung V. Gaborieau, et al. 2008 Lung cancer susceptibility locus at 5p15.33 Nat Genet 40 1404 1406 18978790 10.1038/ng.254 1:CAS:528:DC%2BD1cXhsVWhurvL
32. Y. Wang P. Broderick E. Webb, et al. 2008 Common 5p15.33 and 6p21.33 variants influence lung cancer risk Nat Genet 40 1407 1409 18978787 10.1038/ng.273 1:CAS:528:DC%2BD1cXhsVWhu77F
33. B.A. Weir M.S. Woo G. Getz, et al. 2007 Characterizing the cancer genome in lung adenocarcinoma Nature 450 893 898 17982442 10.1038/nature06358 1:CAS:528:DC%2BD2sXhtl2gsbvM (Pubitemid 350231325)
34. B. Angulo A. Suarez-Gauthier F. Lopez-Rios, et al. 2008 Expression signatures in lung cancer shows a profile for EGFR-mutant tumors and identifies selective PIK3CA overexpression by gene amplification J Pathol 214 347 356 17992665 10.1002/path.2267 1:CAS:528:DC%2BD1cXivVSgt7Y%3D (Pubitemid 351212390)
35. G. Tonon K.K. Wong G. Maulik, et al. 2005 Highresolution genomic profiles of human lung cancer Proc Natl Acad Sci USA 102 9625 9630 15983384 10.1073/pnas.0504126102 1:CAS:528:DC%2BD2MXmsVaktL0%3D (Pubitemid 40981731)
36. P.P. Medina S.D. Castillo S. Blanco, et al. 2009 The SRY-HMG box gene, SOX4, is a target of gene amplification at chromosome 6p in lung cancer Hum Mol Genet 18 1343 1352 19153074 10.1093/hmg/ddp034 1:CAS:528:DC%2BD1MXjsFSjtbw%3D
37. A. Bhattacharjee W.G. Richards J. Staunton, et al. 2001 Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses Proc Natl Acad Sci USA 98 13790 13795 11707567 10.1073/pnas.191502998 1:CAS:528:DC%2BD3MXovVynt7s%3D (Pubitemid 33115977)
38. M.E. Garber O.G. Troyanskaya K. Schluens, et al. 2001 Diversity of gene expression in adenocarcinoma of the lung Proc Natl Acad Sci USA 98 13784 13789 11707590 10.1073/pnas.241500798 1:CAS:528:DC%2BD3MXovVynt7o%3D (Pubitemid 33115976)
39. T. Takeuchi S. Tomida Y. Yatabe, et al. 2006 Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors J Clin Oncol 24 1679 1688 16549822 10.1200/JCO.2005.03.8224 1:CAS:528:DC%2BD28XksVKgtLg%3D (Pubitemid 46622139)
40. P.P. Medina F.J. Slack 2008 microRNAs and cancer: an overview Cell Cycle 7 2485 2492 18719380 1:CAS:528:DC%2BD1cXht1elsbvM
41. S.M. Johnson H. Grosshans J. Shingara, et al. 2005 RAS is regulated by the let-7 microRNA family. RAS is regulated by the let-7 microRNA family Cell 120 635 647 15766527 10.1016/j.cell.2005.01.014 1:CAS:528:DC%2BD2MXis1yhsbs%3D (Pubitemid 40343076)
42. J. Takamizawa H. Konishi K. Yanagisawa, et al. 2004 Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival Cancer Res 64 3753 3756 15172979 10.1158/0008-5472.CAN- 04-0637 1:CAS:528:DC%2BD2cXksVKgurs%3D (Pubitemid 38697282)
43. N. Yanaihara N. Caplen E. Bowman, et al. 2006 Unique microRNA molecular profiles in lung cancer diagnosis and prognosis Cancer Cell 9 189 198 16530703 10.1016/j.ccr.2006.01.025 1:CAS:528:DC%2BD28XivFWjtLw%3D (Pubitemid 43357945)
44. S.L. Yu H.Y. Chen G.C. Chang, et al. 2008 MicroRNA signature predicts survival and relapse in lung cancer Cancer Cell 13 48 57 18167339 10.1016/j.ccr.2007.12.008 1:CAS:528:DC%2BD1cXnsVKmsw%3D%3D (Pubitemid 350309743)
45. M. Barbacid 1987 Ras genes Annu Rev Biochem 56 779 827 3304147 10.1146/annurev.bi.56.070187.004023 1:CAS:528:DyaL2sXkslWlurY%3D
46. Y. Samuels Z. Wang A. Bardelli, et al. 2004 High frequency of mutations of the PIK3CA gene in human cancers Science 304 554 15016963 10.1126/science.1096502 1:CAS:528:DC%2BD2cXjsVGmsbk%3D (Pubitemid 38541907)
47. E. Conde B. Angulo M. Tang, et al. 2006 Molecular context of the epidermal growth factor receptor mutations: evidence for the activation of mTOR/S6K signaling Clin Cancer Res 12 710 717 16467080 10.1158/1078-0432.CCR-05- 1362 1:CAS:528:DC%2BD28XhtFeitbw%3D (Pubitemid 43259849)
48. C.M. Johannessen E.E. Reczek M.F. James, et al. 2005 The NF1 tumor suppressor critically regulates TSC2 and mTOR Proc Natl Acad Sci USA 102 8573 8578 15937108 10.1073/pnas.0503224102 1:CAS:528:DC%2BD2MXlsFCgtrs%3D (Pubitemid 40862777)
49. E. Forgacs E.J. Biesterveld Y. Sekido, et al. 1998 Mutation analysis of the PTEN/MMAC1 gene in lung cancer Oncogene 17 1557 1565 9794233 10.1038/sj.onc.1202070 1:CAS:528:DyaK1cXms1OgtrY%3D
50. A. Yokomizo D.J. Tindall H. Drabkin, et al. 1998 PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers Oncogene 17 475 479 9696041 10.1038/sj.onc.1201956 1:CAS:528:DyaK1cXlsVWlurc%3D
51. V. Stambolic A. Suzuki J.L. de la Pompa, et al. 1998 Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN Cell 95 29 39 9778245 10.1016/S0092-8674(00)81780-8 1:CAS:528:DyaK1cXmslWlsr0%3D (Pubitemid 28458022)
52. S.A. Hawley J. Boudeau J.L. Reid, et al. 2003 Complexes between the LKB1 tumor suppressor, STRADalpha/beta and MO25alpha/beta are upstream kinases in the AMP-activated protein kinase cascade J Biol 2 28 14511394 10.1186/1475-4924-2- 28
53. A. Woods S.R. Johnstone K. Dickerson, et al. 2003 LKB1 is the upstream kinase in the AMP-activated protein kinase cascade Curr Biol 13 2004 2008 14614828 10.1016/j.cub.2003.10.031 1:CAS:528:DC%2BD3sXptVeru7g%3D (Pubitemid 37425212)
54. D.G. Hardie 2003 Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status Endocrinology 144 5179 5183 12960015 10.1210/en.2003-0982 1:CAS:528:DC%2BD3sXpsV2gtL4%3D (Pubitemid 37476044)
55. M.N. Corradetti K. Inoki N. Bardeesy, et al. 2004 Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome Genes Dev 18 1533 1538 15231735 10.1101/gad.1199104 1:CAS:528:DC%2BD2cXlslWnurY%3D (Pubitemid 38868905)
56. J. Carretero P.P. Medina R. Blanco, et al. 2007 Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer Oncogene 26 1616 1625 16953221 10.1038/sj.onc.1209951 1:CAS:528:DC%2BD2sXisFynsLY%3D (Pubitemid 46398737)
57. J.A. Engelman K. Zejnullahu T. Mitsudomi, et al. 2007 MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 1039 1043 17463250 10.1126/science.1141478 1:CAS:528: DC%2BD2sXltlOjt7g%3D (Pubitemid 46799492)
58. L. Chin J. Pomerantz R.A. DePinho 1998 The INK4a/ARF tumor suppressor: one gene-two products-two pathways Trends Biochem Sci 23 291 296 9757829 10.1016/S0968-0004(98)01236-5 1:CAS:528:DyaK1cXls1Ohu7Y%3D (Pubitemid 28461894)
59. M. Hollstein D. Sidransky B. Vogelstein, et al. 1991 p53 mutations in human cancers Science 253 29 53 10.1126/science.1905840
60. A.J. Levine 1997 P53, the cellular gatekeeper for growth and cell division Cell 88 323 331 9039259 10.1016/S0092-8674(00)81871-1 1:CAS:528:DyaK2sXhtFahtLg%3D (Pubitemid 27131374)
61. S.W. Cheng K.P. Davies E. Yung, et al. 1999 c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function Nat Genet 22 102 105 10319872 10.1038/8811 1:CAS:528:DyaK1MXjtVagsLg%3D (Pubitemid 29214815)
62. U. McDermott S.V. Sharma L. Dowell, et al. 2007 Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling Proc Natl Acad Sci USA 104 19936 19941 18077425 10.1073/pnas.0707498104 1:CAS:528:DC%2BD1cXitFWjsw%3D%3D
63. M. Azam R.R. Latek G.Q. Daley 2003 Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL Cell 112 831 843 12654249 10.1016/S0092-8674(03)00190-9 1:CAS:528:DC%2BD3sXivVWjsbY%3D (Pubitemid 36378885)
64. W. Pao V.A. Miller K.A. Politi, et al. 2005 Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med 2 e73 15737014 10.1371/journal.pmed.0020073 (Pubitemid 40629469)